Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR‐Reduced
Observational analysis revealed empagliflozin reduced hospitalization for heart failure in patients, suggesting consistent effects regardless of atrial fibrillation status.
Key Points
Empagliflozin treatment significantly reduced cardiovascular death or hospitalization for heart failure, while showing similar outcomes in patients with and without atrial fibrillation.
A total of 2785 patients were studied after post-hoc analysis, with no significant differences between atrial fibrillation and sinus rhythm for the primary endpoint.
The study compared outcomes between patients with heart failure and reduced ejection fraction and effectively utilized data from the EMPEROR-Reduced trial for analysis.
Findings suggest empagliflozin benefits patients irrespective of atrial fibrillation status, indicating broader applicability of treatments for heart failure.